When Elizabeth was diagnosed with advanced stage lung cancer in April 2015, she was pregnant with her first child. She was told she had virtually no treatment options and had one year left to live. Elizabeth and her oncologist, Dr. Scott Laurie at the Ottawa Cancer Centre, decided to evaluate her cancer with FoundationOne. The test identified multiple alterations, including ROS1, which gave her multiple targeted therapy options. Elizabeth was initially treated with crizotinib and then followed up with lorlatinib as part of a clinical trial. She was then able to have surgery to remove the tumors. Elizabeth is involved in many advocacy efforts, and she hopes that her experience inspires more patients to get comprehensive genomic testing so they can have the opportunity to get targeted treatment options which could manage their disease. And her son Jack is doing great too.
>> Visit Elizabeth’s blog.